nach oben

International Journal of Clinical Oncology

Erschienen in:

26.05.2017 | Original Article

High expression of GRP78/BiP as a novel predictor of favorable outcomes in patients with advanced thymic carcinoma

verfasst von: Yosuke Miura, Kyoichi Kaira, Reiko Sakurai, Hisao Imai, Yoshio Tomizawa, Noriaki Sunaga, Koichi Minato, Takeshi Hisada, Tetsunari Oyama, Masanobu Yamada

Erschienen in: International Journal of Clinical Oncology | Ausgabe 5/2017

Einloggen, um Zugang zu erhalten

Abstract

Background

Glucose-regulated protein (GRP) 78/immunoglobulin heavy chain binding protein (BiP) is a member of the endoplasmic reticulum chaperone family, and its role in various types of human malignancies has recently been investigated. However, the clinicopathological characteristics of GRP78/BiP in advanced thymic carcinoma (ATC) remain unknown. We aimed to examine the relationship between GRP78/BiP expression and the clinical outcomes of ATC patients.

Methods

Thirty-four patients with ATC receiving combination chemotherapy at three institutions between April 1998 and April 2014 were enrolled in this study. We retrospectively collected patient characteristics such as therapeutic efficacy, pathological findings, and survival data from their medical records. We performed immunohistochemical analysis to evaluate the expression of GRP78/BiP in tumor specimens obtained from surgical resection or biopsy.

Results

This study included 21 men (68%) and 13 women (32%) with a median age of 62 years (range 36–75 years). GRP78/BiP overexpression was observed in 65% of the patients (22 of 34 patients). There was no correlation between GRP78/BiP expression and any patient characteristic. Patients with a high level of GRP78/BiP expression had significantly longer overall survival (OS) compared to those with a low level (46.2 vs. 16.8 months, p = 0.04). Multivariate analysis demonstrated that a high level of GRP78/BiP expression was an independent prognostic factor for prolonged OS.

Conclusions

Our findings indicate that the overexpression of GRP78/BiP is a novel predictor of favorable outcomes in patients with ATC who receive combination chemotherapy.

Kelly RJ, Petrini I, Rajan A et al (2011) Thymic malignancies: from clinical management to targeted therapies. J Clin Oncol 29(36):4820–4827. doi:10.1200/jco.2011.36.0487 CrossRefPubMedPubMedCentral

Engels EA, Pfeiffer RM (2003) Malignant thymoma in the United States: demographic patterns in incidence and associations with subsequent malignancies. Int J Cancer 105(4):546–551. doi:10.1002/ijc.11099 CrossRefPubMed

Lemma GL, Lee JW, Aisner SC et al (2011) Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma. J Clin Oncol 29(15):2060–2065. doi:10.1200/jco.2010.32.9607 CrossRefPubMedPubMedCentral

Kondo K, Monden Y (2003) Therapy for thymic epithelial tumors: a clinical study of 1,320 patients from Japan. Ann Thorac Surg 76(3):878–884 (discussion 884–875) CrossRefPubMed

Giaccone G, Ardizzoni A, Kirkpatrick A et al (1996) Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma. A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 14(3):814–820CrossRefPubMed

Agatsuma T, Koizumi T, Kanda S et al (2011) Combination chemotherapy with doxorubicin, vincristine, cyclophosphamide, and platinum compounds for advanced thymic carcinoma. J Thorac Oncol 6(12):2130–2134. doi:10.1097/JTO.0b013e31822e71c0 CrossRefPubMed

Lee AS (2007) GRP78 induction in cancer: therapeutic and prognostic implications. Cancer Res 67(8):3496–3499. doi:10.1158/0008-5472.can-07-0325 CrossRefPubMed

Ma Y, Hendershot LM (2004) The role of the unfolded protein response in tumour development: friend or foe? Nat Rev Cancer 4(12):966–977. doi:10.1038/nrc1505 CrossRefPubMed

Hendershot LM (2004) The ER function BiP is a master regulator of ER function. Mt Sinai J Med 71(5):289–297PubMed

10.

Zhang J, Jiang Y, Jia Z et al (2006) Association of elevated GRP78 expression with increased lymph node metastasis and poor prognosis in patients with gastric cancer. Clin Exp Metastasis 23(7–8):401–410. doi:10.1007/s10585-006-9051-9 PubMed

11.

Dong D, Ni M, Li J et al (2008) Critical role of the stress chaperone GRP78/BiP in tumor proliferation, survival, and tumor angiogenesis in transgene-induced mammary tumor development. Cancer Res 68(2):498–505. doi:10.1158/0008-5472.can-07-2950 CrossRefPubMed

12.

Lee E, Nichols P, Spicer D et al (2006) GRP78 as a novel predictor of responsiveness to chemotherapy in breast cancer. Cancer Res 66(16):7849–7853. doi:10.1158/0008-5472.can-06-1660 CrossRefPubMed

13.

Daneshmand S, Quek ML, Lin E et al (2007) Glucose-regulated protein GRP78 is up-regulated in prostate cancer and correlates with recurrence and survival. Hum Pathol 38(10):1547–1552. doi:10.1016/j.humpath.2007.03.014 CrossRefPubMed

14.

Fu W, Wu X, Li J et al (2010) Upregulation of GRP78 in renal cell carcinoma and its significance. Urology 75(3):603–607. doi:10.1016/j.urology.2009.05.007 CrossRefPubMed

15.

Langer R, Feith M, Siewert JR et al (2008) Expression and clinical significance of glucose regulated proteins GRP78 (BiP) and GRP94 (GP96) in human adenocarcinomas of the esophagus. BMC Cancer 8:70. doi:10.1186/1471-2407-8-70 CrossRefPubMedPubMedCentral

16.

Uramoto H, Sugio K, Oyama T et al (2005) Expression of endoplasmic reticulum molecular chaperone Grp78 in human lung cancer and its clinical significance. Lung Cancer 49(1):55–62. doi:10.1016/j.lungcan.2004.12.011 CrossRefPubMed

17.

Thornton M, Aslam MA, Tweedle EM et al (2013) The unfolded protein response regulator GRP78 is a novel predictive biomarker in colorectal cancer. Int J Cancer 133(6):1408–1418. doi:10.1002/ijc.28137 CrossRefPubMed

18.

Koga K, Matsuno Y, Noguchi M et al (1994) A review of 79 thymomas: modification of staging system and reappraisal of conventional division into invasive and non-invasive thymoma. Pathol Int 44(5):359–367CrossRefPubMed

19.

Travis W, Brambilla E, Muller-Hermelink H et al (2004) World Health Organization Classification of Tumours: pathology and genetics. Tumours of the lung, pleura, thymus and heart. IARC, Lyon

20.

Miura Y, Kaira K, Sakurai R et al. (2016) Prognostic impact of class III β-tubulin and topoisomerase-II in patients with advanced thymic carcinoma who received combination chemotherapy, including taxanes or topoisomerase-II inhibitors. Oncol Lett (in press)

21.

Lee E, Nichols P, Groshen S et al (2011) GRP78 as potential predictor for breast cancer response to adjuvant taxane therapy. Int J Cancer 128(3):726–731. doi:10.1002/ijc.25370 CrossRefPubMedPubMedCentral

22.

Yerushalmi R, Raiter A, Nalbandyan K et al (2015) Cell surface GRP78: a potential marker of good prognosis and response to chemotherapy in breast cancer. Oncol Lett 10(4):2149–2155. doi:10.3892/ol.2015.3579 PubMedPubMedCentral

23.

Wei PL, Kuo LJ, Wang W et al (2012) Silencing of glucose-regulated protein 78 (GRP78) enhances cell migration through the upregulation of vimentin in hepatocellular carcinoma cells. Ann Surg Oncol 19(Suppl 3):S572–S579. doi:10.1245/s10434-011-2055-y

24.

Jamora C, Dennert G, Lee AS (1996) Inhibition of tumor progression by suppression of stress protein GRP78/BiP induction in fibrosarcoma B/C10ME. Proc Natl Acad Sci USA 93(15):7690–7694CrossRefPubMedPubMedCentral

25.

Fu Y, Lee AS (2006) Glucose regulated proteins in cancer progression, drug resistance and immunotherapy. Cancer Biol Ther 5(7):741–744CrossRefPubMed

26.

Pyrko P, Schonthal AH, Hofman FM et al (2007) The unfolded protein response regulator GRP78/BiP as a novel target for increasing chemosensitivity in malignant gliomas. Cancer Res 67(20):9809–9816. doi:10.1158/0008-5472.can-07-0625 CrossRefPubMed

27.

Tanimoto R, Sakaguchi M, Abarzua F et al (2010) Down-regulation of BiP/GRP78 sensitizes resistant prostate cancer cells to gene-therapeutic overexpression of REIC/Dkk-3. Int J Cancer 126(7):1562–1569. doi:10.1002/ijc.24764 PubMed

28.

Davidson DJ, Haskell C, Majest S et al (2005) Kringle 5 of human plasminogen induces apoptosis of endothelial and tumor cells through surface-expressed glucose-regulated protein 78. Cancer Res 65(11):4663–4672. doi:10.1158/0008-5472.can-04-3426 CrossRefPubMed

29.

Burikhanov R, Zhao Y, Goswami A et al (2009) The tumor suppressor Par-4 activates an extrinsic pathway for apoptosis. Cell 138(2):377–388. doi:10.1016/j.cell.2009.05.022 CrossRefPubMedPubMedCentral

30.

Verfaillie T, Garg AD, Agostinis P (2013) Targeting ER stress induced apoptosis and inflammation in cancer. Cancer Lett 332(2):249–264. doi:10.1016/j.canlet.2010.07.016 CrossRefPubMed

31.

Kaira K, Toyoda M, Shimizu A et al (2016) Decreasing expression of glucose-regulated protein GRP78/BiP as a significant prognostic predictor in patients with advanced laryngeal squamous cell carcinoma. Head Neck 38(10):1539–1544. doi:10.1002/hed.24471 CrossRefPubMed

32.

Kaira K, Toyoda M, Shimizu A et al (2016) Prognostic significance of GRP78/BiP expression in patients with stage III/IV hypopharyngeal squamous cell carcinoma. Neoplasma 63(3):477–483. doi:10.4149/319_151002n513

33.

Gifford JB, Huang W, Zeleniak AE et al (2016) Expression of GRP78, master regulator of the unfolded protein response, increases chemoresistance in pancreatic ductal adenocarcinoma. Mol Cancer Ther 15(5):1043–1052. doi:10.1158/1535-7163.mct-15-0774 CrossRefPubMed

34.

Cerezo M, Lehraiki A, Millet A et al (2016) Compounds triggering ER stress exert anti-melanoma effects and overcome BRAF inhibitor resistance. Cancer Cell. doi:10.1016/j.ccell.2016.04.013

Titel: High expression of GRP78/BiP as a novel predictor of favorable outcomes in patients with advanced thymic carcinoma
verfasst von: Yosuke Miura
Kyoichi Kaira
Reiko Sakurai
Hisao Imai
Yoshio Tomizawa
Noriaki Sunaga
Koichi Minato
Takeshi Hisada
Tetsunari Oyama
Masanobu Yamada
Publikationsdatum: 26.05.2017
Verlag: Springer Japan
Erschienen in: International Journal of Clinical Oncology / Ausgabe 5/2017
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-017-1142-x

Neu im Fachgebiet Onkologie

24.04.2024 | DGIM 2024 | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

High expression of GRP78/BiP as a novel predictor of favorable outcomes in patients with advanced thymic carcinoma

Abstract

Background

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Background

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2017

Risk factors for paraaortic lymph node metastasis in endometrial cancer

Post-recurrence chemotherapy for mesothelioma patients undergoing extrapleural pneumonectomy

Salvage endoscopic nasopharyngectomy for local recurrent or residual nasopharyngeal carcinoma: a 10-year experience

Predictors for recurrent/persistent high-grade intraepithelial lesions and cervical stenosis after therapeutic conization: a retrospective analysis of 522 cases

A phase II study of 5-fluorouracil/L-leucovorin/oxaliplatin (mFOLFOX6) in Japanese patients with metastatic or unresectable small bowel adenocarcinoma

The survival and prognosticators of peritoneal cytology-positive gastric cancer patients who received upfront gastrectomy and subsequent S-1 chemotherapy

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie